CAPR
Capricor Therapeutics Inc
Halal Rating :
Last Price
$13.70
Last updated:
Market Cap
-
7D Change
7.67%
1 Year Change
230.0%
Company Overview
Industries
Exchange
Next Earnings Date
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for the treatment and prevention of serious diseases. The company's lead candidate, CAP-1002, is being developed for treating Duchenne muscular dystrophy and other indications. Their technology platform is centered on cardiosphere-derived cells and exosomes.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $2.26m | $15.27m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $3.97m | $15.56m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $4.91m | $15.17m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Capricor Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.